US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Novo Nordisk A/S B Shares ADRhedged

21.22

+0.32001.53%

Volume:738.00

Turnover:15.65K

Market Cap:3.40M

PE:- -

High:21.26

Open:21.26

Low:21.22

Close:20.90

52wk High:49.22

52wk Low:19.91

Shares:160.00K

Float Shares:60.00K

Volume Ratio:0.24

T/O Rate:1.23%

Dividend:0.65

Dividend Rate:3.08%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk Targets Real-World Heart and Kidney Outcomes for Ozempic in China

Novo Resources Completes Tranche 1 Placement and Issues Cleansing Notice

Eli Lilly Targets Employer GLP-1 Coverage to Compete with Novo Nordisk

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Novo Nordisk A/S Stock Rises Wednesday, Outperforms Market

Novo Nordisk A/S Stock Moved Up by 3.81% on Mar 4: Drivers Behind the Movement

Novo Nordisk Reportedly Warned Over Use of Misleading Claims in Ozempic Ad

MT Newswires Live

Option traders moderately bearish in Novo Nordisk with shares down 2.87%

Morgan Stanley Upgrades Novo Nordisk to Equalweight From Underweight, Adjusts Price Target to $40 From $42

MT Newswires Live

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Price Weakness

Simply Wall St.

Novo Nordisk : Morgan Stanley Raises to Equal-Weight From Underweight; Cuts Target Price to $40 From $42

THOMSON REUTERS

Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley

Novo Nordisk Employees Elect New Board Representatives Ahead of March AGM

Novo Nordisk A/S Stock Falls Monday, Outperforms Market

Eli Lilly Stock (LLY) Falls as Rival Novo Nordisk Expands Weight-Loss Pill Manufacturing

Novo Nordisk Cut to Neutral From Buy by Goldman Sachs

Novo Nordisk to Invest $507.1 Million to Upgrade Athlone, Ireland Production Site

MT Newswires Live

Novo Nordisk downgraded to Neutral from Buy at Goldman Sachs

Novo Nordisk Allocates Over €400 Million to Upgrade Irish Facility for Global Wegovy Production Boost

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NVOH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","market":"US","secType":"STK","nameCN":"Novo Nordisk A/S B Shares ADRhedged","latestPrice":21.22,"timestamp":1772815155288,"preClose":20.9,"halted":0,"volume":738,"delay":0,"changeRate":0.01531100478468901,"floatShares":60000,"shares":160000,"eps":0,"marketStatus":"Trading","change":0.32,"latestTime":"03-06 11:46:07 EST","open":21.26,"high":21.26,"low":21.22,"amount":15645.178601999998,"amplitude":0.001914,"askPrice":21.24,"askSize":100,"bidPrice":21.12,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772830800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":20.9,"dividendRate":0.030829,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":20.9,"preClose":20.9,"latestTime":"16:10 EST","volume":6,"amount":125.4,"timestamp":1772745004690,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.235055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOH\",,,,,undefined,":{"symbol":"NVOH","floatShares":60000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.235055,"shares":160000,"dividePrice":0.6542,"high":21.26,"amplitude":0.001914,"preClose":20.9,"low":21.22,"week52Low":19.91,"pbRate":"--","week52High":49.2239,"institutionHeld":0,"latestPrice":21.22,"eps":0,"divideRate":0.030829,"volume":738,"delay":0,"ttmEps":0,"open":21.26,"prevYearClose":27.4362,"prevWeekClose":20.176,"prevMonthClose":20.176,"prevQuarterClose":27.4362,"fiveDayClose":20.176,"twentyDayClose":23.2926,"sixtyDayClose":25.8391},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"NVOH","amount":0.48798,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"Novo Nordisk A/S B Shares ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2025-09-16","symbol":"NVOH","amount":0.16566,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"Novo Nordisk A/S (B Shares) ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-23","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOH\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-16","recordDate":"2025-09-16","paymentDate":"2025-09-23","value":0.16566,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.48798,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2617631223","title":"Novo Nordisk Targets Real-World Heart and Kidney Outcomes for Ozempic in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2617631223","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617631223?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:32","pubTimestamp":1772814779,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study A Retrospective Database Study to Compare Cardiovascular and Ren...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-targets-real-world-heart-and-kidney-outcomes-for-ozempic-in-china?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-targets-real-world-heart-and-kidney-outcomes-for-ozempic-in-china?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","NVO","BK4585","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","BK4588","BK4532","NVOH","BK4007","LU0154236417.USD","LU1093756168.USD","NVOX"],"gpt_icon":0},{"id":"2617356166","title":"Novo Resources Completes Tranche 1 Placement and Issues Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2617356166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617356166?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:09","pubTimestamp":1772806140,"startTime":"0","endTime":"0","summary":"The latest update is out from Novo Resources ( ($TSE:NVO) ). Novo Resources has completed the first tranche of a previously announced placement, is...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-resources-completes-tranche-1-placement-and-issues-cleansing-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-resources-completes-tranche-1-placement-and-issues-cleansing-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4599","BK4585","NVOX","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVO","BK4007","LU0154236417.USD","LU1093756168.USD","BK4588"],"gpt_icon":0},{"id":"1146337298","title":"Eli Lilly Targets Employer GLP-1 Coverage to Compete with Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=1146337298","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146337298?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:41","pubTimestamp":1772718077,"startTime":"0","endTime":"0","summary":"Eli Lilly has launched \"Employer Connect,\" offering a net price of $449 per month for the new multi-dose Zepbound. The program integrates with partners such as Teladoc Health and GoodRx to expand access to obesity medications. Novo-Nordisk A/S remains the primary competitor.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","IE00BK4W5L77.USD","IE00BJJMRX11.SGD","IE0001KFT4U8.USD","LU1093756168.USD","LU0198837287.USD","LU1712237335.SGD","SG9999015978.USD","LU1035775433.USD","LU1127390331.HKD","LU2108987350.USD","LU2237443382.USD","LU2237443549.SGD","LU0158827948.USD","LU2360106947.USD","LU2265009873.SGD","LU2468319806.SGD","LU0354030511.USD","LU0823434740.USD","IE00B2B36J28.USD","LU0820561818.USD","LU1551013425.SGD","LU0096364046.USD","BK4534","SG9999001176.SGD","LU1291159041.SGD","LU0289739699.SGD","LU2552382132.HKD","LU0079474960.USD","LU2324357040.USD","LU2471134879.HKD","LU2756315318.SGD","LU0353189680.USD","LU2028103732.USD","SG9999014906.USD","SG9999014880.SGD","LU2746668974.SGD","LU2462157665.USD","LU0061475181.USD","LU0882574055.USD","LU2746668461.USD","LU2213496289.HKD","LU2087625088.SGD","LU2089283258.USD","LU2023250330.USD","LU0786609619.USD","LU1988902786.USD","LU0106261372.USD","SG9999013999.USD","BK4599","LU0823416689.USD","LU0122379950.USD","LU0432979614.USD","BK4533","IE00B4JS1V06.HKD","ELIS","LU1720051017.SGD","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU2552382058.USD","LU0787776722.HKD","LU1868836757.USD","SGXZ99366536.SGD","LU0203201768.USD","NVOH","LU2896262040.SGD","LU2264538146.SGD","LU2023250504.SGD","LU2168564149.EUR","IE00BKVL7J92.USD","LU2236285917.USD","LU0158827781.USD","IE0002141913.USD","SG9999018857.SGD","LU0320765059.SGD","NVO","LU2112291526.USD","LU2168564065.EUR","SG9999014914.USD","LU2361045086.USD","LU1720051108.HKD","LU2456880835.USD","LU0109391861.USD","SG9999015986.USD","IE00BK4W5M84.HKD","IE00BFSS8Q28.SGD","LU2168564222.USD","LU2211815571.USD","LU2491050154.USD","LLII","LU0689472784.USD","IE00B1BXHZ80.USD","LU0466842654.USD","BK4144","LU0672654240.SGD","LU2237443622.USD","LU0823434583.USD","LU1623119135.USD","SG9999014898.SGD","LU0114720955.EUR","LU2602419157.SGD","BK4585","LU1093756325.SGD","LU1069344957.HKD","LU1551013342.USD","LU1804176565.USD","LU2750360641.GBP","SGXZ57979304.SGD","ELIL","LU1868837300.USD","IE00BJLML261.HKD","LU0354030438.USD","LU2089984988.USD","LU2168564495.EUR","LU1868836591.USD","LU0417517546.SGD","LU0964807845.USD","LU2237443465.HKD","BK4588","LU0154236417.USD","IE00B1XK9C88.USD","IE0009355771.USD","LU0097036916.USD","LU1232071149.USD","LU1983299246.USD","LU2237443895.HKD","IE00B775H168.HKD","LU2111349929.HKD","LU2756315664.SGD","LU2417539215.USD","LU0316494557.USD","LU1280957306.USD","LU0820562030.AUD","LU2471134523.USD","LU2237443978.SGD","IE00BFTCPJ56.SGD","BK4007","IE0004445015.USD","IE00BJT1NW94.SGD","LU0109394709.USD","LU1057294990.SGD","IE00BFSS7M15.SGD","LU2357305700.SGD","LU1548497426.USD","LU2237438978.USD","LU0225283273.USD","IE00BZ1G4Q59.USD","LU1629891620.HKD","LU2750360997.AUD","LU0256863811.USD","LU1023059063.AUD","IE00BKDWB100.SGD","BK4590","LLYX","SG9999018865.SGD","LU0234572021.USD","NVOX","IE0004445239.USD","SG9999015952.SGD","LU2491049909.HKD","LU2271345857.HKD","IE00BN29S564.USD","LU2063271972.USD","LU0640476718.USD","LU2552382215.SGD","LU1323610961.USD","LU2361044865.SGD","GB00BDT5M118.USD","LU0058720904.USD","LU0889565916.HKD","LU0456855351.SGD","SGXZ31699556.SGD","LU2461242641.AUD","IE00BKPKM429.USD","LU0385154629.USD","LLY","IE00BWXC8680.SGD","LU0471298694.HKD","LU1064131342.USD","LU1868837136.USD","BK4581","LU2089284900.SGD","LU0256863902.USD","LU2106854487.HKD","SG9999001176.USD","LU0006306889.USD","BK4532","LU1145028129.USD","IE00B7KXQ091.USD","LU1917777945.USD","BK4516","LU1267930730.SGD","LU2471134796.USD","LU2491050071.SGD","SG9999015945.SGD","LU2471134952.CNY","SG9999017495.SGD","LU1974910355.USD","LU0094547139.USD","SGXZ81514606.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0203202063.USD","LU0353189763.USD","LU0708995401.HKD","LU0882574139.USD","SGXZ51526630.SGD","LU1989771016.USD","LU1366192091.USD","IE00BJJMRY28.SGD","LLYZ","LU0323591593.USD","LU0210536198.USD","LU1868836914.USD","LU0471298777.SGD","LU2023251221.USD","LU2168563687.JPY","LU0683600562.USD","LU0266013472.USD","LU0820561909.HKD","LU2361044949.HKD","LU1814569148.SGD","IE0005OL40V9.USD","LU0238689110.USD"],"gpt_icon":0},{"id":"2617542199","title":"Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542199?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:59","pubTimestamp":1772711940,"startTime":"0","endTime":"0","summary":"Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3249981/0/en/Lexicon-Pharmaceuticals-Reports-Fourth-Quarter-2025-Financial-Results-and-Provides-Clinical-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXRX","BK4139","BK4585","NVOH","BK4532","HCM","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","IE00BKVL7J92.USD","IND","NVOX","BK4531","BK4599","LU1093756168.USD","LU0154236417.USD","BK4588"],"gpt_icon":1},{"id":"2617557686","title":"Novo Nordisk A/S Stock Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557686","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617557686?lang=en_us&edition=fundamental","pubTime":"2026-03-05 01:02","pubTimestamp":1772643720,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S rose 6.0% to DKK245.45 Wednesday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 2.5% to 2,564.49.The stock's rise  snapped a three-day losing streak.The company closed DKK403.95 below its 52-week high of DKK649.40, which the company achieved on March 5, 2025.Trading volume was 7,277,512, compared to the 50-day average trading volume of 9,466,226.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","BK4007","BK4588","BK4585","BK4599","LU1093756325.SGD","NVO","LU1093756168.USD","BK4532","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOX","LU0154236417.USD"],"gpt_icon":1},{"id":"2616436551","title":"Novo Nordisk A/S Stock Moved Up by 3.81% on Mar 4: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2616436551","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616436551?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:15","pubTimestamp":1772637327,"startTime":"0","endTime":"0","summary":"• FDA approved expanded indications for Sogroya.\n• Novo Nordisk partnered with Vivtex for new biologic treatments.\n• Morgan Stanley upgraded Novo Nordisk's stock rating.","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/stocks/261645391-market-movers-nvo-20260304","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7104","NVO","BK4585","BK4588","LU1093756168.USD","LU1093756325.SGD","NVOH","BK4007","BK4139","LU0154236417.USD","BK4532","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOX"],"gpt_icon":1},{"id":"2616343245","title":"Novo Nordisk Reportedly Warned Over Use of Misleading Claims in Ozempic Ad","url":"https://stock-news.laohu8.com/highlight/detail?id=2616343245","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616343245?lang=en_us&edition=fundamental","pubTime":"2026-03-04 19:24","pubTimestamp":1772623464,"startTime":"0","endTime":"0","summary":"Novo Nordisk  received a warning from the US Food and Drug Administration over the use of false and misleading claims in an ad for the company's Ozempic product, news outlets reported Tuesday.According to the reports, the ad suggested that all patients with type 2 diabetes Ozempic are eligible for Ozempic's approved indications, but the approved use is for patients who have other conditions apart from diabetes.The company was given 15 days to respond to the warning, the news outlets said.Separately, the FDA warned 30 telehealth companies over false or misleading claims over compounded GLP-1 products published on their respective websites, implying that their products are the same with FDA-approved products.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","LU1093756325.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK7104","BK4599","NVO","NVOX","BK4588","BK4007","BK4585","NVOH"],"gpt_icon":1},{"id":"2616372757","title":"Option traders moderately bearish in Novo Nordisk with shares down 2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616372757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616372757?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:45","pubTimestamp":1772574318,"startTime":"0","endTime":"0","summary":"Option traders moderately bearish in Novo Nordisk (NVO), with shares down $1.08 near $36.67. Options volume roughly in line with average with 140k ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-novo-nordisk-with-shares-down-2-87-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-novo-nordisk-with-shares-down-2-87-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","NVOH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","NVOX","BK4532","IE00BKVL7J92.USD","BK4007","LU1093756325.SGD","BK4585","BK4588","LU0154236417.USD"],"gpt_icon":0},{"id":"2616342716","title":"Morgan Stanley Upgrades Novo Nordisk to Equalweight From Underweight, Adjusts Price Target to $40 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342716","media":"MT Newswires Live","labels":["rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342716?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:16","pubTimestamp":1772540207,"startTime":"0","endTime":"0","summary":"Novo Nordisk A/S (NVO) has an average rating of overweight and mean price target of $50.98, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","LU1093756325.SGD","NVO","BK4588","IE00BKVL7J92.USD","BK4532","BK4585","BK7104","NVOX","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4007","NVOH","BK4599"],"gpt_icon":0},{"id":"2616341578","title":"Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616341578","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616341578?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:08","pubTimestamp":1772536096,"startTime":"0","endTime":"0","summary":"Barclays analyst James Gordon CFA maintained a Hold rating on Novo Nordisk today and set a price target of DKK270.00. According to TipRanks, Gordon...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-novo-nordisk-0qiu-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-hold-rating-for-novo-nordisk-0qiu-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0154236417.USD","LU1093756325.SGD","NVOH","BK4585","NVOX","BK4599","CFA","NVO","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4532","BK4007"],"gpt_icon":0},{"id":"2616434675","title":"Assessing Novo Nordisk (NYSE:NVO) Valuation After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2616434675","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616434675?lang=en_us&edition=fundamental","pubTime":"2026-03-03 18:27","pubTimestamp":1772533655,"startTime":"0","endTime":"0","summary":"Event-driven snapshot of Novo Nordisk (NYSE:NVO)\nNovo Nordisk (NYSE:NVO) has drawn investor attention after its recent share performance, with the stock showing a 0.8% move over the past day and declines over the past week, month, and past 3 months.\nSee our latest analysis for Novo Nordisk.\nThat 0.8% 1 day share price gain comes after a sharp 36.5% 30 day share price decline and a 27.9% year to date share price fall, while the 1 year total shareholder return of 56.9% and 3 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/assessing-novo-nordisk-nysenvo-valuation-after-recent-share-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/assessing-novo-nordisk-nysenvo-valuation-after-recent-share-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK4007","BK4599","LU1093756325.SGD","NVO","NVOH","IE00BKVL7J92.USD","BK4532","BK4585","NVOX","LU0154236417.USD"],"gpt_icon":1},{"id":"2616478311","title":"Novo Nordisk : Morgan Stanley Raises to Equal-Weight From Underweight; Cuts Target Price to $40 From $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2616478311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616478311?lang=en_us&edition=fundamental","pubTime":"2026-03-03 15:53","pubTimestamp":1772524389,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0FK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVOX","BK4585","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","BK4588","BK4599","BK4532","LU1093756168.USD","LU1093756325.SGD","NVOH"],"gpt_icon":0},{"id":"2616316888","title":"Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2616316888","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616316888?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:55","pubTimestamp":1772520931,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Thibault Boutherin upgraded Novo Nordisk to a Hold today and set a price target of $40.00. According to TipRanks, Boutherin ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-nvo-was-upgraded-to-a-hold-rating-at-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-nvo-was-upgraded-to-a-hold-rating-at-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0267386448.USD","LU0154236417.USD","LU1363072403.SGD","LU1989772923.USD","LU0795875086.SGD","NVOX","NVOH","LU1791710582.SGD","BK4127","LU0314104364.USD","BK4581","LU1791710400.SGD","LU0158827948.USD","LU1093756325.SGD","LU1720051108.HKD","LU2357305700.SGD","LU0528227936.USD","LU1244550494.USD","LU2089284900.SGD","LU1162221912.USD","LU0971096721.USD","LU0098860793.USD","BK4599","LU0006306889.USD","LU0106831901.USD","BK4534","LU1732799900.SGD","LU0106261372.USD","BK4504","LU1720051017.SGD","LU1989772840.SGD","LU2347655156.SGD","LU0234570918.USD","LU1074936037.SGD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0795875169.SGD","LU1244550577.SGD","LU2111349929.HKD","LU0557290698.USD","BK4585","LU1732800096.USD","NVO","LU1244550221.USD","LU1548497426.USD","LU0225283273.USD","BK4516","LU0320765646.SGD","BK4588","LU0912757837.SGD","BK4007","LU2133065610.SGD","LU2023251221.USD","LU2271345857.HKD","LU2089283258.USD","LU1093756168.USD","LU1668664300.SGD","LU2028103732.USD","LU0158827781.USD","IE00BKVL7J92.USD","BK4532"],"gpt_icon":0},{"id":"2616035731","title":"Novo Nordisk Employees Elect New Board Representatives Ahead of March AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2616035731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616035731?lang=en_us&edition=fundamental","pubTime":"2026-03-03 01:26","pubTimestamp":1772472388,"startTime":"0","endTime":"0","summary":"An update from Novo Nordisk ( ($NVO) ) is now available. On 2 March 2026, Novo Nordisk employees completed the election of new employee representat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-employees-elect-new-board-representatives-ahead-of-march-agm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-employees-elect-new-board-representatives-ahead-of-march-agm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4229","BK4599","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","NVO","NVOH","NVOX","BK4585","BK4588","BK4195","LU1093756325.SGD","LU1093756168.USD","BK4007","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2616540053","title":"Novo Nordisk A/S Stock Falls Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2616540053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616540053?lang=en_us&edition=fundamental","pubTime":"2026-03-03 01:02","pubTimestamp":1772470920,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S shed 0.2% to DKK237.35 Monday on what proved to be an overall poor trading session for the stock market, with the OMX Nordic 40 Index falling 1.4% to 2,580.41.This was the stock's second consecutive day of losses.The company closed DKK413.85 below its 52-week high of DKK651.20, which the company achieved on March 3, 2025.Trading volume was 8,389,428, compared to the 50-day average trading volume of 9,225,505.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","BK4007","LU1093756168.USD","NVOX","NVO","LU0154236417.USD","NVOH","BK4588","BK4532","BK4599","BK4585","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2616017354","title":"Eli Lilly Stock (LLY) Falls as Rival Novo Nordisk Expands Weight-Loss Pill Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2616017354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616017354?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:55","pubTimestamp":1772470512,"startTime":"0","endTime":"0","summary":"Eli Lilly’s ($LLY) stock is down 2% on reports that rival Novo Nordisk ($NVO) is spending more than $500 million to expand the manufacturing of its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/eli-lilly-stock-lly-falls-as-rival-novo-nordisk-expands-weight-loss-pill-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/eli-lilly-stock-lly-falls-as-rival-novo-nordisk-expands-weight-loss-pill-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0820561909.HKD","LU0006306889.USD","SG9999015978.USD","LU2168563687.JPY","LU2361045086.USD","LU0689472784.USD","LU2471134952.CNY","IE00B4JS1V06.HKD","IE00BKVL7J92.USD","LU0256863811.USD","LU2237438978.USD","LU2552382215.SGD","LU2111349929.HKD","LU2237443895.HKD","BK4534","IE0002141913.USD","LU2552382132.HKD","IE00B2B36J28.USD","LU0094547139.USD","IE00BKDWB100.SGD","LU0385154629.USD","LU2089283258.USD","LU1551013425.SGD","LU2213496289.HKD","LU1548497426.USD","LU2756315664.SGD","LLYX","SGXZ81514606.USD","LU2168564065.EUR","LU2756315318.SGD","LU1988902786.USD","LU0106261372.USD","LU0353189763.USD","LU0820562030.AUD","LU2746668974.SGD","LU2360106947.USD","IE00B775H168.HKD","LU0158827781.USD","LU2237443622.USD","IE00B7KXQ091.USD","LU0154236417.USD","LU0432979614.USD","IE0001KFT4U8.USD","IE00BJJMRZ35.SGD","LU2023250504.SGD","LLII","LU2112291526.USD","BK4007","IE0004445015.USD","LU2168564495.EUR","LU1868836914.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0471298777.SGD","BK4585","LU0683600562.USD","LU1366192091.USD","IE00BN29S564.USD","SG9999014898.SGD","LU0353189680.USD","IE00B1XK9C88.USD","BK4581","LU1720051108.HKD","BK4599","LU0114720955.EUR","LU1023059063.AUD","LU2491050071.SGD","LU0234572021.USD","LU0058720904.USD","LU0238689110.USD","LU2028103732.USD","LU0708995401.HKD","LU0823416689.USD","LU2089984988.USD","LU2462157665.USD","LU1093756325.SGD","LU0097036916.USD","LU2491049909.HKD","LU0109391861.USD","LU0316494557.USD","IE00BK4W5L77.USD","LU1061106388.HKD","LU1127390331.HKD","IE00BJJMRX11.SGD","IE00BK4W5M84.HKD","LU0787776722.HKD","LU2023250330.USD","LU0203201768.USD","LU2324357040.USD","SG9999014906.USD","LU1868837300.USD","LU2471134523.USD","LLY","LU1093756168.USD","SG9999001176.USD","LU0061475181.USD","LU2750360997.AUD","LU1291159041.SGD","LU1551013342.USD","LU2023251221.USD","LU0225283273.USD","LU2106854487.HKD","LU0823434740.USD","LU1035775433.USD","LU2361044865.SGD","LU0640476718.USD","LU0823434583.USD","LU1280957306.USD","LU0471298694.HKD","LU0323591593.USD","SGXZ31699556.SGD","LU0122379950.USD","LU0289739699.SGD","LU1145028129.USD","LU2063271972.USD","LU2089284900.SGD","LU2471134879.HKD","LU0417517546.SGD","LU2552382058.USD","ELIS","LU0256863902.USD","LU2211815571.USD","LU0158827948.USD","LU2491050154.USD","SG9999001176.SGD","IE0005OL40V9.USD","IE00BJLML261.HKD","LU1064131342.USD","LU2461242641.AUD","ELIL","BK4588","LU0882574139.USD","IE00B1BXHZ80.USD","LU1868836591.USD","LU2271345857.HKD","IE00BJJMRY28.SGD","LU0456855351.SGD","LU1623119135.USD","LU0203202063.USD","BK4516","LU1267930730.SGD","LU1804176565.USD","LU2264538146.SGD","LU2456880835.USD","LU0672654240.SGD","SG9999013999.USD","SG9999018865.SGD","SGXZ57979304.SGD","LU0354030511.USD","SG9999015945.SGD","LU0354030438.USD","BK4533","SG9999017495.SGD","LU1814569148.SGD","LU1629891620.HKD","IE00BWXC8680.SGD","LU2750360641.GBP","LU2361044949.HKD","LU2468319806.SGD","LU2087625088.SGD","IE00BFSS7M15.SGD","LU2237443382.USD","LU2237443978.SGD","LU1323610961.USD","LU1868836757.USD","SG9999014880.SGD","LU0198837287.USD","LU2108987350.USD","LU2746668461.USD","IE00BKPKM429.USD","LU0882574055.USD","SGXZ99366536.SGD","LU2471134796.USD","LU0964807845.USD","LU0109394709.USD","LU2357305700.SGD","IE0004445239.USD","LU0320765059.SGD","IE00BFSS8Q28.SGD","SG9999015986.USD","LLYZ","BK4532","LU2265009873.SGD","LU2896262040.SGD","LU2168564222.USD","LU2237443465.HKD","SGXZ51526630.SGD","NVOX","LU0889565916.HKD","SG9999015952.SGD","LU2417539215.USD","LU0096364046.USD","LU0820561818.USD","LU2602419157.SGD","IE00BFTCPJ56.SGD","LU2168564149.EUR","SG9999014914.USD","LU1989771016.USD","NVO","GB00BDT5M118.USD","LU1057294990.SGD","LU1868837136.USD","IE00BZ1G4Q59.USD","IE0009355771.USD","LU0466842654.USD","LU1917777945.USD","LU1720051017.SGD","LU2237443549.SGD","LU1069344957.HKD","NVOH","LU1712237335.SGD","LU0079474960.USD","LU1974910355.USD","LU0266013472.USD","LU0210536198.USD","LU2236285917.USD","LU0943347566.SGD","LU1232071149.USD","SG9999018857.SGD","LU0786609619.USD","LU1983299246.USD"],"gpt_icon":0},{"id":"2616196331","title":"Novo Nordisk Cut to Neutral From Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616196331","media":"Dow Jones","labels":["rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616196331?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:13","pubTimestamp":1772453580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:13 ET (12:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1868836757.USD","IE0004086264.USD","IE0004091025.USD","LU0345770308.USD","BK4599","NVOH","BK4504","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","IE00BSNM7G36.USD","LU0251142724.SGD","BK4552","IE00B19Z3581.USD","LU1868836914.USD","LU2237443382.USD","LU2237443622.USD","BK4007","LU2237443895.HKD","LU2471134523.USD","LU0345770993.USD","LU0048573561.USD","IE00B19Z3B42.SGD","LU0251131958.USD","LU1668664300.SGD","LU1093756325.SGD","IE00BFXG1179.USD","LU1894683264.USD","LU0742534661.SGD","NVO","LU1868837300.USD","LU1791807156.HKD","LU2237443549.SGD","BK4516","LU1894683348.USD","NVOX","LU2237443465.HKD","LU2471134796.USD","LU2750360997.AUD","LU0061475181.USD","LU2265009873.SGD","GSX","LU2471134952.CNY","LU1804176565.USD","LU1868836591.USD","IE0034235188.USD","LU2750360641.GBP","BK4532","LU0096364046.USD","BK4127","LU2237438978.USD","BK4533","IE0002270589.USD","LU1868837136.USD","LU2471134879.HKD","BK4585","LU2237443978.SGD","LU0106831901.USD","LU1093756168.USD","BK4588"],"gpt_icon":0},{"id":"2616933667","title":"Novo Nordisk to Invest $507.1 Million to Upgrade Athlone, Ireland Production Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2616933667","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616933667?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:50","pubTimestamp":1772445051,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Monday it is planning to invest 432 million euros  to upgrade its tabletting facility in Athlone, Ireland.This tabletting site will offer additional production capacity for current and future GLP-1 treatments, according to the Danish drug manufacturer.Novo Nordisk said it has already started construction work on the facility, with completion anticipated from the end of next year through 2028.Shares of the company were down 1.1% in recent Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","BK4588","BK7104","NVOX","BK4007","NVOH","BK4599","BK4585","LU1093756168.USD","LU1093756325.SGD","NVO","IE00BKVL7J92.USD","BK4532"],"gpt_icon":1},{"id":"2616387059","title":"Novo Nordisk downgraded to Neutral from Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616387059","media":"TIPRANKS","labels":["rating"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616387059?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:25","pubTimestamp":1772443509,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst James Quigley downgraded Novo Nordisk (NVO) to Neutral from Buy with a price target of $41, down from $63. The firm cut estim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-downgraded-to-neutral-from-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-downgraded-to-neutral-from-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0251131958.USD","NVOX","IE0002270589.USD","LU2237443549.SGD","LU2237443895.HKD","NVOH","IE0034235188.USD","LU0061475181.USD","IE00BZ1G4Q59.USD","LU0048573561.USD","BK4532","LU2237443465.HKD","LU2750360997.AUD","LU1868836914.USD","BK4516","BK4599","LU1894683348.USD","BK4127","LU2237443382.USD","IE00B19Z3B42.SGD","LU0251142724.SGD","LU1093756325.SGD","BK4504","LU1791807156.HKD","LU1868837136.USD","LU2471134523.USD","LU2265009873.SGD","IE0004091025.USD","BK4585","LU0096364046.USD","LU2237438978.USD","LU2237443978.SGD","LU2471134796.USD","NVO","LU0106831901.USD","LU0154236417.USD","LU1804176565.USD","BK4533","BK4552","IE0004086264.USD","BK4007","LU1668664300.SGD","LU1868836757.USD","LU2237443622.USD","LU2471134952.CNY","LU0345770308.USD","LU1868836591.USD","LU1894683264.USD","LU2750360641.GBP","LU0742534661.SGD","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU1868837300.USD","GSX","LU0345770993.USD","BK4588","IE00B19Z3581.USD","BK4550","IE00BSNM7G36.USD","LU2471134879.HKD","LU1093756168.USD"],"gpt_icon":0},{"id":"1130612406","title":"Novo Nordisk Allocates Over €400 Million to Upgrade Irish Facility for Global Wegovy Production Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=1130612406","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130612406?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:11","pubTimestamp":1772442696,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO.US) will invest €432 million ($507 million) to upgrade one of its plants in Ireland for manufacturing its blockbuster weight-loss drug Wegovy, targeting markets outside the United...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0154236417.USD","NVO","NVOH","LU1093756325.SGD","EUO","IE00BKVL7J92.USD","LU1093756168.USD","NVOX","IE00BZ1G4Q59.USD","FXE","BK4599","BK4588","BK4585","BK4007"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":198,"code":"91000000","status":"200"}]}}